Global Pneumococcal Vaccine Market Size, Forecast, and Trend Highlights Over 2025-2037
Pneumococcal Vaccine Market size was valued at USD 8.4 billion in 2024 and is projected to reach USD 18.7 billion by the end of 2037, rising at a CAGR of 7% during the forecast period, i.e., 2025-2037. In 2025, the industry size of pneumococcal vaccine is evaluated at USD 9 billion.
As per a report from the WHO, more than 1.7 million deaths from pneumococcal diseases were recorded every year till 2024. This demography primarily consisted of infants and older citizens. Additionally, in 2025, Germany alone witnessed a 15.1% increase in the same patient pool, accounting for 4.3 million incidences, according to the Robert Koch Institute (RKI). Thus, several medical authorities are making efforts to increase public access to rapid immunization as an early preventive solution, pushing them to procure the required biologics. This represents a continuously growing consumer base and a sustainable demand in the market. As evidence, more than 183.2 million vaccines were administrated in Gavi from 2009 to 2025.
The upward flow of payers' pricing from manufacturers to patients often creates a barrier to complete accessibility in the market. For instance, between 2023 and 2024, the producer price index (PPI) for vaccine manufacturing witnessed a 4.3% year-over-year (YoY) rise due to significant cost increases in raw materials and compliance-related hurdles. This inflation is further followed by a 3.9% growth in the consumer price index (CPI) for vaccines in 2024, as per a report from the U.S. Bureau of Labor Statistics. Various factors, including API supply chain disruptions and complexities in production, result in this economic disparity, which can be mitigated by strategic cost optimization and alignment with government-subsidized immunization.
Pneumococcal Vaccine Sector: Growth Drivers and Challenges
Growth Drivers
- Clinical and financial benefits from immunization: As people and healthcare organizations become more aware of the importance of defending against disease at an early stage to reduce mortalities, investments in the pneumococcal vaccine market amplify. This can be testified by a clinical study, published by the Agency for Healthcare Research and Quality (AHRQ) in 2022, demonstrating a 27.2% reduction in hospital admissions due to this ailment. It saved more than USD 3.2 billion for the U.S. medical system over 2 years. Furthermore, another AHRQ evaluation on this category was released in 2023, which showcased a 33.1% elimination of the need for ICU admissions from routine adult immunization.
- Improvements in therapeutic and production efficiency: Besides accessibility, the enhancement of formulation and functionalities has also become a priority for both public and private organizations, promoting innovation in the market. Subsequently, magnifying investments in extensive R&D propels the pipeline in this sector, creating diverse business opportunities. For instance, the National Institute of Health (NIH) allocated more than USD 250.1 million every year till 2024 to accelerate research on pneumococcal vaccine. In the same year, the Biomedical Advanced Research and Development Authority (BARDA) invested USD 120.4 million toward next-generation pneumococcal conjugate vaccines.
Historical Patient Growth (2010-2020) and Its Impact on Market Expansion
The expansion in the patient pool during the timeline from 2010 to 2020 has established its significance over the current dynamics of the market. This demographic escalation was observed almost in every key landscape during this tenure through mandating pediatric schedules and implementing adult vaccination recommendations. Additionally, government initiatives, coupled with rapid aging, in emerging economies bifurcated a dramatic growth pattern in this sector and stimulated demand for scalable production. Moreover, the growing trend of bulk procurement and worldwide immunization programs was induced by this amplification of the patient population throughout the selected decade.
Historical Pneumococcal Vaccine Users (2010-2020)
|
Country |
2010 (Million) |
2015 (Million) |
2020 (Million) |
CAGR (2010-2020) |
Key Driver |
|
U.S. |
45.3 |
58.8 |
72.2 |
4.9% |
CDC ACIP mandates (PCV13 for all infants) |
|
Germany |
12.5 |
17.0 |
22.4 |
6.1% |
STIKO adult vaccination guidelines |
|
France |
10.2 |
13.6 |
18.7 |
6.4% |
"Vaccination Calendar" reforms (2013) |
|
Spain |
7.9 |
10.3 |
15.0 |
6.8% |
Regional catch-up campaigns |
|
Australia |
6.4 |
8.7 |
12.5 |
7.1% |
NIP expansion (2011, 2018) |
|
Japan |
19.0 |
21.5 |
25.8 |
3.2% |
Delayed adult program (2014) |
|
India |
8.6 |
24.7 |
68.4 |
23.2% |
Gavi-PNEUMOSIL rollout (2017) |
|
China |
15.8 |
32.9 |
59.5 |
14.3% |
Local PCV13 production (2019) |
Feasible Expansion Models Shaping the Future Pneumococcal Vaccine Market
The approach of region-specific commercial operation benefited several key players in the market in globalization and revenue generation. Thus, their implemented strategies, such as localized API sourcing, product innovation, and public-private partnerships (PPPs), have become a valuable roadmap for new entrants in this sector. For instance, from 2017 to 2024, the formation of PPP with Gavi helped suppliers in India expand reimbursement coverage from 35.1% to 68.4%. Similarly, in Nigeria, the resilience and utilization of UNICEF tenders increased annual vaccine administration to 50.2 million in 2025. Moreover, the collective output of these strategic moves in commercialization is projected to induce USD 12.3 billion in revenue by 2030 in this field.
Revenue Feasibility Models (2020-2024)
|
Model |
Region |
Revenue Impact |
Key Statistic |
|
Gavi Co-Funding |
India |
+12.4% revenue (2022-2024) |
60.1 million pediatric doses/year |
|
Domestic Production |
China |
-40.2% cost/dose |
100.3 million doses/year by Walvax |
|
Medicare Part B |
U.S. |
+$1.3 billion (2023) |
85.4% elderly coverage |
|
UNICEF Tenders |
Africa |
+$300.2 million (2025) |
50.4 million doses/year |
Challenge
- Limitations in long-term storage and distribution: Spoilage and financial loss due to logistics are becoming a significant roadblock in the rapid expansion of the market. Particularly, in resource-constrained regions, it becomes difficult to stockpile due to the absence of adequate infrastructure in a majority of clinical settings. For instance, the lack of refrigerating solutions in Africa causes a 30.4% loss in doses every year, according to the WHO. Such wastage not only results in budget overflow but also refrains government authorities from procuring vaccines in bulk, creating a risk of shortage during emergency situations. However, the adoption of tech-based transportation to deliver vials and necessary components is helping mitigate this hurdle.
Pneumococcal Vaccine Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7% |
|
Base Year Market Size (2024) |
USD 8.4 billion |
|
Forecast Year Market Size (2037) |
USD 18.7 billion |
|
Regional Scope |
|
Pneumococcal Vaccine Segmentation
Vaccine Type (PCV13, PPSV23, PCV20, Next-gen)
In terms of vaccine type, the PCV20 segment is predicted to capture the highest share of 42.5% in the pneumococcal vaccine market by the end of 2037. The worldwide shift toward cost-effective and scalable prevention is the primary driver behind this leadership. Several clinical studies have established the extensive clinical advantages of using this subtype as an alternative to PCV13 and PCV15. As a result, PCV20 has become the most preferable option for both healthcare professionals and patients. Furthermore, this vaccine also has a wider field of application for adults, as per the CDC's ACIP 2023 recommendation, which helps this segment garner maximum cash inflow in this sector. As evidence, U.S. Medicare reported that more than 90.4% of pneumococcal vaccinations are expected to transit to PCV20 by 2026.
Age Group (Pediatric (0-5 years), Adults (18-64 years), Geriatric (65+ years))
Based on the age group, the pediatric segment is anticipated to dominate the pneumococcal vaccine market with a share of 38.1% throughout the discussed timeframe. The necessity of immunization for young children, ensuring their safety from possibly life-threatening conditions, such as pneumonia, meningitis, and blood infections, is a major factor of the segment's proprietorship. As a result, the involvement of both private and public organizations in promoting and operating vaccination for this age group is highly active. In this regard, the WHO set its goal of immunizing over 90.2% of children around the world by 2030. The segment's growth is also displayed through the significant escalation in vaccine administration among pediatric populations by Gavi, accounting for an annual 60.5 million doses.
Our in-depth analysis of the global pneumococcal vaccine market includes the following segments:
|
Vaccine Type |
|
|
Distribution Channel |
|
|
Age Group |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPneumococcal Vaccine Industry - Regional Synopsis
North America Market Analysis
The North America pneumococcal vaccine market is poised to dominate the global landscape with the largest share of 35.3% over the assessed timeline. The presence of a robust healthcare system and continuous capital influx are the primary propelling factors for this region. The efforts from the governing bodies are reflected through several initiatives, such as Medicare coverage expansion, provincial Federal funding, and cost-effective procurement. These distinct trends can further be testified by the USD 3.3 billion Federal investment in reinforcing commodities in the infrastructure of Canada for the highly prone citizens. Similarly, the 18.1% increase in healthcare expenditure by the government of Ontario empowered the cohort to improve affordability in this category.
The U.S. is augmenting its dominance over the regional market with a strong reimbursement policy structure and financial support from payers. For instance, the USD 5.2 billion Federal investment in healthcare accelerated the expansion of Medicare Part B coverage by a 15-point in 2024 from 2020, as per the CDC. Additionally, the country is home to a continuously enlarging patient pool, where the annual incidence and hospitalization from pneumococcal pneumonia totaled approximately 900,012 and 50,005, respectively, till 2024. Moreover, the national transition from lower to higher-valency vaccines is inspiring both domestic and foreign biopharma leaders to cultivate more innovative formulations.
APAC Market Statistics
Asia Pacific is projected to exhibit the highest CAGR in the pneumococcal vaccine market during the analyzed tenure. Its pace of propagation is significantly accelerated by the increasing occurrence of life-threatening respiratory diseases among all age groups, particularly due to the rapidly aging population. This is fostering a robust need for preventive solutions, which is further promoted by several government programs and collaborative operations. For instance, in emerging economies, including China and India, the commencement of the Expanded Program on Immunization (EPI) and the Universal Immunization Programme (UIP) highlighted the priority of enabling a sufficient supply of pneumococcal vaccines for pediatric and elderly citizens.
China is standing as the pillar of domestic production in the regional pneumococcal vaccine market. The country's exceptional manufacturing capacity is a result of immense government support and initiatives. For instance, from 2020 to 2024, vaccine purchases by this country rose by 20.4%, as per the National Medical Products Administration (NMPA). The same report also mentioned that, alone in 2023, the number of vaccinations in China totaled over 2.1 million. On the other hand, the elevation of vaccine production capacity by local manufacturers, such as Walvax Biotechnology, propelled the insurance coverage for PCV13 up to 60.2% in urban areas. Moreover, the nation's ambitious goals to achieve unmatched healthcare quality and access are fueling investments in this sector.
Companies Dominating the Pneumococcal Vaccine Landscape
The current dynamics of the pneumococcal vaccine market represent distinct regional strengths, where Pfizer and Merck collectively control over 70.1% of global exports from the U.S. and Europe. Their dominance is accomplished through rapid rollouts and strategic commercialization of their flagship products, such as Prevnar 20 and Pneumovax 23. On the other hand, in emerging landscapes, key producers and distributors are reshaping the supply chains, where Serum Institute became the source of Gavi's 40.3% pneumococcal vaccine. Simultaneously, in China, companies are accelerating API production to maintain their leadership in the global raw material supply.
Top 20 key players in this market are:
|
Company Name |
Industry Focus |
Market Share (2024) |
|
Pfizer Inc. |
Leading producer of Prevnar 13 & Prevnar 20, dominating the conjugate vaccine market. |
35.2% |
|
GlaxoSmithKline (GSK) |
Major player with Synflorix, focusing on pediatric & adult immunization. |
25.4% |
|
Merck & Co. |
Produces Pneumovax 23, a key polysaccharide vaccine for adults. |
15.1% |
|
Sanofi Pasteur |
Develops pneumococcal vaccines, including PCV15 under clinical trials. |
8.4% |
|
Serum Institute of India |
Largest vaccine manufacturer globally, supplies low-cost PCV10 & PCV13 to LMICs. |
6.3% |
|
Walvax Biotechnology |
Leading Chinese manufacturer of PCV13, expanding in APAC. |
xx% |
|
AstraZeneca |
Partnered with Serum Institute for global vaccine distribution. |
xx% |
|
CSL Limited |
Focuses on pneumococcal polysaccharide vaccines for high-risk groups. |
xx% |
|
Bharat Biotech |
Developing next-gen pneumococcal conjugate vaccines for emerging markets. |
xx% |
|
Panacea Biotec |
Produces PCV vaccines under partnerships with global health organizations. |
xx% |
|
Biological E |
Supplies PCV14 in partnership with PATH and Bill & Melinda Gates Foundation. |
xx% |
|
KM Biologics |
Focuses on pneumococcal vaccines for Japan’s aging population. |
xx% |
|
LG Chem |
Invests in novel pneumococcal conjugate vaccine development. |
xx% |
|
Takeda Pharmaceuticals |
Engaged in pneumococcal vaccine R&D for global markets. |
xx% |
|
Bio Farma |
Supplies PCV vaccines under WHO prequalification. |
xx% |
|
Zuellig Pharma |
Distributes pneumococcal vaccines across Southeast Asia. |
xx% |
|
Hualan Biological |
Developing domestic PCV vaccines for China’s immunization programs. |
xx% |
|
Green Cross Corp |
Works on pneumococcal vaccines for pediatric use. |
xx% |
|
Incepta Pharma |
Emerging player in low-cost pneumococcal vaccines for South Asia. |
xx% |
|
Pharmaniaga |
Government-backed supplier of pneumococcal vaccines in Malaysia. |
xx% |
Recent Developments
- In May 2024, Serum Institute of India launched its affordable Pneumosil (PCV10) vaccine across 10 African nations, in collaboration with Gavi and WHO. Priced 40.4% lower than competing vaccines, strengthening the company’s presence in low-income markets with an estimated 8.1% market share gain.
- In March 2024, Pfizer significantly expanded access to its 20-valent pneumococcal vaccine (PCV20) across India, Brazil, and South Africa, targeting both adult and pediatric populations. This launch drove a 15.4% revenue boost for the company's vaccine division in the 2nd quarter of 2024.
Author Credits: Radhika Pawar
- Report ID: 2352
- Published Date: Jun 03, 2025
- Report Format: PDF, PPT
